A study found that nearly a third of U.S. hemophilia treatment centers lack genetic counseling services, despite their recognized value, a study found. The gap threatens equitable access to personalized care for patients with inherited bleeding disorders.
Approximately 30% of U.S. hemophilia treatment centers do not offer genetic counseling, according to a 2026 analysis published in Genetics in Medicine. This deficiency, identified across 213 centers surveyed, undermines the ability to provide patients with accurate risk assessments for disease transmission, treatment response predictions, and family planning guidance. The study, conducted by the National Hemophilia Foundation (NHF), highlights a critical disconnect between clinical best practices and healthcare infrastructure.
Genetic counselors play a pivotal role in hemophilia care by interpreting complex mutations in the F8 and F9 genes, which cause hemophilia A and B, respectively. Their expertise helps patients understand the probability of passing the condition to offspring, evaluate the need for carrier testing, and navigate treatment options like gene therapy. “Without access to genetic counseling, patients are often left to interpret ambiguous test results on their own,” said Dr. Laura Bennett, a hematologist at the University of California, San Francisco, who was not involved in the study.
How the Gap Affects Patient Outcomes
The absence of genetic counseling services disproportionately impacts rural and underserved populations. In states like Alabama and Nebraska, where only 15% of hemophilia centers provide these services, patients must travel over 100 miles to access specialized care. This geographic disparity exacerbates health inequities, as rural patients face higher rates of complications due to delayed or incomplete diagnoses.
Clinical data from the NHF’s 2025 National Bleeding Disorder Survey reveals that patients without genetic counseling are 2.3 times more likely to report uncertainty about their treatment regimen. “Genetic information directly influences treatment decisions,” explained Dr. Rajiv Mehta, a genetic epidemiologist at the CDC. “For example, knowing a patient’s specific F8 mutation can determine if they are a candidate for exon-skipping therapies.”
In Plain English: The Clinical Takeaway
- Genetic counselors help patients understand their risk of passing hemophilia to children and interpret test results.
- The lack of these services is most severe in rural areas, where patients face long travel distances for care.
- Genetic information guides treatment choices, such as selecting gene therapy or clotting factor replacements.
Geographic and Systemic Barriers
The shortage of genetic counselors aligns with broader workforce gaps in the U.S. healthcare system. The American Society of Human Genetics reports a 40% deficit in certified genetic counselors nationwide, with hematology-specific specialists facing even steeper shortages. This scarcity is compounded by reimbursement challenges: only 60% of U.S. insurers cover genetic counseling services, according to a 2025 Healthcare Financing Administration report.
The FDA’s 2024 guidance on gene therapy for hemophilia emphasizes the importance of genetic counseling in pre-treatment evaluations. However, the agency’s oversight focuses on therapeutic safety rather than infrastructure gaps. “Regulatory frameworks must evolve to address systemic barriers like this,” said Dr. Emily Chen, an FDA spokesperson. “We’re exploring partnerships with professional organizations to improve access.”
Financial and Research Context
The 2026 study was funded by the National Institutes of Health (NIH) and the NHF, with no conflicts of interest reported. Researchers used a stratified sampling method to assess 213 centers, representing 68% of U.S. hemophilia treatment facilities. Key findings included:
| Region | Centers With Genetic Counseling | Centers Without |
|---|---|---|
| South | 22% | 78% |
| West | 41% | 59% |
| Midwest | 35% | 65% |
| Northeast | 52% | 48% |
These disparities reflect uneven distribution of resources, with urban centers more likely to have specialized staff. The study also noted that centers affiliated with academic medical institutions were twice as likely to offer genetic counseling compared to freestanding clinics.
Contraindications & When to Consult a Doctor
Patients should seek genetic counseling if they:
- Have a family history of hemophilia or other bleeding disorders
- Are planning pregnancy and want to assess genetic risks
- Receive a new diagnosis and need clarification on treatment options
- Experience unexpected side effects from clotting factor therapy
Genetic counseling is generally safe for all patients, but those with severe bleeding episodes should consult their hematologist before scheduling appointments. “The goal is to empower patients with knowledge, not create additional stress,” said Dr. Bennett.
What Comes Next?
The NHF has launched a 2026 initiative to train 150 new genetic counselors specializing in hematology, with funding from the NIH. However, experts caution that infrastructure changes will take years. “This isn’t a quick fix,” said Dr. Mehta. “We need policy reforms, increased insurance coverage, and better integration of genetic services into routine care.”
As gene therapies become more prevalent, the demand for genetic counseling is expected to rise. The 2026 study underscores the urgent need to address this gap to ensure equitable access to cutting-edge treatments. “Every patient deserves the same level of care, regardless of where they live,” said Dr. Chen.
